Radiopharmaceuticals for the study of inflammatory processes: A review

Nuclear Medicine Communications

Volumn 18, Issue 5, 1997, Pages 437-455

  Chianelli, M ^a   Mather, S J ^b   Martin Comin, J ^c   Signore, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AVIDIN; BIOTIN; CELL ADHESION MOLECULE; CHEMOTACTIC PEPTIDE; CYTOKINE; GALLIUM CITRATE GA 67; GLUTATHIONE; GRANULOCYTE ANTIBODY; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; HUMAN IMMUNOGLOBULIN; INFECTON TC 99M; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2; J 001X; LEUKOCYTE IN 111; LIPOSOME IN 111; LIPOSOME TC 99M; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BW 250 183; NANOCOLL TC 99M; OKT 4; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SUBSTANCE P; SYNTHETIC PEPTIDE; THROMBOCYTE IN 111; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; CELL LABELING; CHRONIC INFLAMMATION; DIAGNOSIS; HUMAN; INFECTION; INFLAMMATION; ISOTOPE LABELING; LEUKOCYTE; LYMPHOCYTE ACTIVATION; NUCLEAR MEDICINE; PATHOPHYSIOLOGY; REVIEW;

EID: 0031007266     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006231-199705000-00009     Document Type: Review

References (136)

1. Roitt I. Essential immunology, 8th edn. Oxford: Blackwell Scientific, 1994.
2. Becker W. The contribution of nuclear medicine to the patient with infection. Eur J Nucl Med 1995; 22: 1195-1211.
3. Krenning E, Kwekkeboom D, Pauwels S, Kvols L, Reubi J. Somatostatin receptor scintigraphy. In: Freeman LM, Weissman H, eds. Nuclear medicine annual. New York: Raven Press, 1995: 1-50.
4. Corstens F, Van der Meer J. Chemotactic peptides: New locomotion for imaging infection? J Nucl Med 1991; 32: 491-494.
5. Zakhireh B, Thakur M, Malech H et al. Indium-111-labeled polymorphonuclear leukocytes: Viability, random migration, chemotaxis, bactericidal capacity and ultrastructure. J Nucl Med 1979; 20: 741-747.
6. Thakur M, Coleman R, Welch M. Indium-111-labelled leukocytes for the localization of abscesses: Preparation, analysis, tissue distribution and comparison with gallium-67 citrate in dogs. J Lab Clin Med 1977; 89: 217-228.
7. Thakur M, Segal A, Louis L et al. Indium-111-labelled cellular blood components: Mechanism of labelling and intracellular location in human neutrophils. J Nucl Med 1977; 18: 1022-1026.
8. Silvester D, Waters S. Dosimetry of radiolabelled white blood cells. Int J Nucl Biol 1983; 10: 141-144.
9. Thakur M, McAfee J. The significance of chromosomal aberrations in indium-111-labelled lymphocytes. J Nucl Med 1984; 25: 922-927.
10. Becker W, Schomann E, Fischbach W, Börner WB, Gruner K. Comparison of Tc-99m-HMPAO and In-111-oxine labelled granulocytes in man: First clinical results. Nucl Med Commun 1988; 9: 435-447.
11. Costa D, Lui D, Ell P. White cells radiolabelled with 111In and 99mTc: A study of relative sensitivity and in vivo viability. Nucl Med Commun 1988; 9: 725-731.
12. Furno A, Gallo R, Gambetti M, Basile C. Radiation induced chromosomal damage to lymphocytes is usual in 99mTc-HMPAO leukocyte preparations. In: Martin-Comin J, Thakur ML, Piera C, Roca M, Lomeña F, eds. Radiolabelled blood elements: Recent advances in techniques and applications. New York: Plenum Press, 1994: 177-182.
13. Thierens H, Vral A, Haelst JV et al. Lymphocyte labelling with technetium-99m-HMPAO: A radiotoxicity study using the micronucleus assay. J Nucl Med 1992; 33: 1167-1174.
14. Peters A. The utility of 99mTc-HMPAO-leukocytes for imaging infection. Sem Nucl Med 1994; 24: 110-127.
15. Saverymuttu S, Peters A, Crofton M et al. 111-Indium autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985; 26: 955-960.
16. Mertens W, Power J. Utility of 111-In-labelled leukocytes in patients completing high dose interleukin-2 therapy: A pilot study. Nucl Med Commun 1994; 15: 73-80.
17. Lavender J, Goldman J, Arnot R, Thakur M. Kinetics of indium-111-labelled lymphocytes in normal subjects and in patients with Hodgkin's disease. Br Med J 1977; 2: 797-799.
18. Wagstaff J, Gibson C, Thatcher N et al. A method for following human lymphocyte traffic using indium-111 oxine labelling. Clin Exp Immunol 1981; 43: 435-442.
19. Wagstaff J, Gibson C, Thatcher N et al. Human lymphocyte traffic assessed by indium-111 oxine labelling: Clinical observations. Clin Exp Immunol 1981; 43: 443-449.
20. Kaldany A, Hill T, Wentworth S et al. Trapping of peripheral blood lymphocytes in the pancreas of patients with acute-onset insulin dependent diabetes mellitus. Diabetes 1982; 31: 463-466.
21. Gallina D, Pelletier D, Doherty P et al. 111-Indium-labelled lymphocytes do not image or label the pancreas of BB/W rats. Diabetologia 1985; 28: 143-147.
22. Fisher B, Packard B, Read E et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 7: 250-261.
23. Swift R, Danpure H, Osman S et al. Imaging of metastatic colorectal cancer with tumour activated killer lymphocytes. Lancet 1991; 337: 1511-1512.
24. Griffith K, Read E, Carrasquillo J. In vivo distribution of adoptively transferred 111-Indium-labelled TIL and PBL in patients with metastatic melanoma. J Natl Cancer Inst 1989; 81: 1709-1715.
25. Mazzoni G, Lee S, Tomer A, Gittes R. Indium-labeled presensitised T cells for the diagnosis of graft rejection. J Surg Res 1992; 52: 85-88.
26. Read E, Keenan A, Carter C, Yolles P, Davey R. In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med 1990; 31: 999-1006.
27. Catafau A, Lomeña F, Ricart M et al. Indium-111-labeled platelets in monitoring human pancreatic transplants. J Nucl Med 1989; 30: 470-475.
28. Lomeña F, Piera C. Clinical application of radiolabelled platelets: Kidney and pancreas transplantation. In: Martin-Comin J, Thakur ML, Piera C, Roca M, Lomeña F, eds. Radiolabelled blood elements: Recent advances in techniques and applications. New York: Plenum Press, 1994: 335-338.
29. 67Ga-citrate. J Nucl Med 1969; 10: 103-105.
30. Halpern S, Hagan P. Gallium-67-citrate imaging in neoplastic and inflammatory diseases. In: Freeman LM, Weissman H, eds. Nuclear medicine annual. New York: Raven Press, 1980: 219-265.
31. Wassie E, Buscombe J, Miller R, Ell P. 67-Ga scintigraphy in HIV antibody positive patients: A review of its clinical usefulness. Br J Radiol 1994; 67: 349-352.
32. Sohn M, Jones B, Whiting JJ et al. Distribution of gallium-67 in normal and hypotransferrinemic tumour-bearing mice. J Nucl Med 1993; 34: 2135-2143.
33. Borman T, Johnson R, Sherman F. Gallium scintigraphy for the diagnosis of septic arthritis and osteomyelitis in children. J Pediatr Orthop 1986; 6: 317-325.
34. Kao C, Wang S, Liao S, Lin W, Hsu C. Usefulness of gallium-67-citrate scans in patients with acute disseminated tuberculosis and comparison with chest x-rays. J Nucl Med 1993; 34: 1918-1921.
35. Sulavik S, Spencer R, Palestro C et al. Specificity and sensitivity of distinctive chest radiographic and/or 67-Ga images in the noninvasive diagnosis of sarcoidosis. Chest 1993; 103: 403-409.
36. m-human immunoglobulin imaging in human immunodeficiency virus-positive patients with fever of undetermined origin. Nucl Med Commun 1991; 12: 583-592.
37. Schrijver MD, Streule K, Senekowitsch R, Fridrich R. Scintigraphy of inflammation with nanometer-sized colloidal tracers. Nucl Med Commun 1987; 8: 895-908.
38. McAfee J, Gagne G, Subramanian G, Schneider R. The localisation of indium-111-leucocytes, gallium-67, polyclonal IgG and other radioactive agents in acute focal inflammatory lesions. J Nucl Med 1991; 32: 2126-2131.
39. Streule K, Schrijver MD, Fridrich R. 99mTc-labelled HSA-nanocolloid versus 111-In oxine-labelled granulocytes in detecting skeletal septic processes. Nucl Med Commun 1988; 9: 56-67.
40. Liberatore M, Clemente M, Iurilli A et al. Scintigraphic evaluation of disease activity in rheumatoid arthritis: A comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med 1992; 19: 853-857.
41. Frick M, Loken M, Goldberg M, Simmons R. Use of 99mTc-sulphur colloid in evaluation of renal transplant complications. J Nucl Med 1976; 17: 181-183.
42. Massengill S, Pena D, Drane W, Fennell R, Richard G. Technetium-99m sulfur colloid accumulation as a predictor of acute renal transplant rejection. Transplantation 1992; 54: 969-973.
43. Wheeler J, Slack N, Duncan A, Palmer H, Harvey R. Tc-99m-nanocolloids in inflammatory bowel disease. Nucl Med Commun 1990; 11: 127-133.
44. Styles C, Schmidt R, Holt S. Detection of abscesses with diffusible tracers. Int J Nucl Med Biol 1985; 12: 145-149.
45. Rubin R, Young L, Hansen P et al. Specific and nonspecific imaging of localised Fisher immunotype 1. Pseudomonas aeruginosa infection with radiolabelled monoclonal antibody. J Nucl Med 1988; 29: 651-656.
46. Rubin R, Fischman A, Needleman M. Radiolabelled, non-specific, polyclonal human immunoglobulin in the detection of focal inflammation by scintigraphy: Comparison with gallium-67 citrate and technetium-99m-labelled albumin. J Nucl Med 1989; 30: 385-389.
47. Fischman A, Rubin R, Khaw B et al. Detection of acute inflammation with 111In-labelled nonspecific polyclonal IgG. Sem Nucl Med 1988; 18: 335-344.
48. Morrel E, Tompkins R, Fischmann A et al. Autoradiographic method for quantitation of radiolabelled proteins in tissues using indium-111. J Nucl Med 1989; 30: 1538-1545.
49. Fischman A, Rubin R, White J et al. Localization of Fc and Fab fragments of nonspecific polyclonal IgG at focal sites of inflammation. J Nucl Med 1990; 31: 1199-1205.
50. Calame W, Feitsma H, Ensing G et al. Binding of 99mTc-labelled polyclonal human immunoglobulins to bacteria as a mechanism for scintigraphic detection of infection. Eur J Nucl Med 1991; 18: 396-400.
51. Saptogino A, Becker W, Wolf F. 99mTc-labelled polyclonal human immunoglobulins for localization of inflammatory sites: Early in vitro results. Nucl Med 1989; 29: 54-55.
52. Oyen W, Claessens R, Van der Meer J, Corstens F. Biodistribution and kinetics of radiolabelled proteins in rats with focal infection. J Nucl Med 1992; 33: 338-394.
53. Claessens R, Koenders E, Boerman O et al. Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. Eur J Nucl Med 1995; 22: 212-219.
54. Spinelli F, Milella M, Sara R et al. The value of Tc-99m-labelled human immunoglobulin scanning in the evaluation of Crohn's disease (abstract). Eur J Nucl Med 1990; 16: 436.
55. De Bois MHW, Arndt JAW, Van der Velde EA et al. Tc-99m human immunoglobulin: A reliable method to detect joint activity in rheumatoid arthritis. J Rheumatol 1992; 19: 1371-1376.
56. Sciuk J, Brandau W, Vollet B et al. Comparison of technetium-99m polyclonal immunoglobulin and technetium-99m monoclonal antibodies for imaging chronic osteomyelitis. Eur J Nucl Med 1991; 18: 401-407.
57. Larcos G, McLarty A, McGregor C et al. Evaluation of 99m-Tc nonspecific polyclonal IgG in the detection of rejection in a single lung transplant canine model. Nucl Med Commun 1993; 14: 64-69.
58. Signore A, Barone R, Procaccini E et al. In vivo measurement of immunoglobulin accumulation in the pancreas of recent onset type 1 diabetic patients. Clin Exp Rheumatol 1996; 14 (suppl. 15): S41-S45.
59. Buscombe J, Oyen W, Miller R et al. Indium-111 labelled human polyclonal immunoglobulin: Identifying focal infection in patients positive for human immunodeficiency virus (HIV). J Nncl Med 1993; 34: 1621-1625.
60. Mairal L, Lima PD, Martin-Comin J et al. Simultaneous administration of 111In-human immunoglobulin and 99mTc-HMPAO labelled leukocytes in inflammatory bowel disease. Eur J Nucl Med 1995; 22: 664-670.
61. Oyen W, Van Horn J, Ciaessens R et al. Diagnosis of bone, joint and joint prosthesis infections with indium-111 labelled human immunoglobulin G scintigraphy. Radiology 1992; 182: 195-199.
62. Kleijn ED, Oyen W, Claessens R, Corstens F, Van der Meer J. Scintigraphy with In-111-labelled human polyclonal immunoglobulin G (In-111-IgG) in patients with fever of unknown origin (FUO) (abstract). Nucl Med Commun 1992; 13: 626.
63. Hnatowich D, Virzi F, Ruskowski M. Investigation of avidin and biotin for imaging investigation. J Nucl Med 1987; 28: 1294-1302.
64. Paganelli G, Magnani P, Zito F et al. Three-step monoclonal tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960-5966.
65. Rusckowski M, Fritz B, Hnatowich D. Localization of infection using streptavidin and biotin: An alternative to nonspecific polyclonal immunoglobulin. J Nucl Med 1992; 33: 1810-1815.
66. Samuel A, Paganelli G, Chiesa R et al. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med 1996; 37: 55-61.
67. Rusckowski M, Paganelli G, Hnatowich D et al. Imaging osteomyelitis with streptavidin and indium-111-labeled biotin. J Nucl Med 1996; 37: 1655-1662.
68. Nässander U, Storm G, Peeters P, Crommelin D. Liposomes. In: Chasin M, Langer R, eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1990: 261-338.
69. Morgan J, Williams L, Howard C. Technetium-labelled liposome imaging for deep seated infection. Br J Radiol 1985; 58: 35-39.
70. Williams B, O'Sullivan M, Saggu G et al. Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis. Ann Rheum Dis 1987; 46: 314-318.
71. Boerman O, Storm G, Oyen W et al. Sterically stabilised liposomes labeled with indium-111 to image focal infection. J Nucl Med 1995; 36: 1639-1644.
72. Ercan M, Unlenen E, Atkas A. 99mTc-glutathione for imaging inflammatory lesions. Nucl Med Commun 1994; 15: 533-539.
73. Duman Y, Burak Z, Ercan M et al. Clinical evaluation of metastases of malignant melanoma imaging with 99m-Tc-glutathione and 99m-Tc-anti-melanoma antibody: A comparative study. Nucl Med Commun 1995; 16: 927-935.
74. Becker W, Goldenberg G, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Sem Nucl Med 1994; 24: 1-13.
75. Thakur M, Marcus C, Henneman P et al. Imaging inflammatory diseases with neutrophil-specific technetium-99m-labeled monoclonal antibody anti-SSEA-1. J Nucl Med 1996; 37: 1789-1795.
76. Baum R, Hentel A, Bosslet K et al. First use of Tc-99m labelled monoclonal antibody directed against the T cell receptor for immunoscintigraphic detection of transplant rejection (abstract). Eur J Nucl Med 1990; 16: S163.
77. Marcus C, Thakur M, Huynh T et al. Imaging rheumatic joint disease with anti-T lymphocyte antibody OKT-3. Nucl Med Commun 1994; 15: 824-830.
78. Becker W, Emmrich F, Horneff G et al. Imaging rheumatoid arthritis specifically with technetium-99m CD4-specific (T-helper lymphocytes) antibodies. Eur J Nucl Med 1990; 17: 156-159.
79. Kinne R, Becker W, Schwab J et al. Comparison on 99mTc-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulins for imaging inflammed joints in rheumatoid arthritis. Nucl Med Commun 1993; 14: 667-675.
80. Thedrez P, Paineau J, Jacques Y et al. Biodistribution of an anti-interleukin 2 receptor monoclonal antibody in rat recipients of a heart allograft, and its use as a rejection marker in gamma scintigraphy. Transplantation 1989; 48: 367-371.
81. Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunology Today 1992; 13: 106-112.
82. Bellen J, Bannister K, Russ G et al. Radioiodination and in vitro activity of a monoclonal antibody to human ICAM-1: Potential use in allograft rejection (abstract). Eur J Nucl Med 1994; 21: S26.
83. Keelan E, Chapman P, Binns R, Peters A, Haskard D. Imaging vascular endothelial activation: An approach using radiolabeled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin. J Nucl Med 1994; 35: 276-281.
84. Keelan E, Licence S, Peters A, Binns R, Haskard D. Characterisation of E-selectin expression in vivo with use of a radiolabelled monoclonal antibody. Am J Physiol 1994; 266: H279-H290.
85. Bosslet K, Auerbach B, Hoffken H, Joseph K. Frequency and relevance of the human anti-mouse immunoglobulin (HAMA) response in immunoscintigraphy. Nuklearmedizin 1989; 28: 149-159.
86. Fischmann A, Babich J, Strauss H. A ticket to ride: Peptide radiopharmaceuticals. J Nucl Med 1993; 34: 2253-2262.
87. Hazra D, Britton K, Lahiri V et al. Immunotechnological trends in radioimmunotargeting: From 'magic bullet' to 'smart bomb'. Nucl Med Commun 1995; 16: 66-75.
88. Khaw B, Strauss H, Narula J. 'Magic bullets': From muskets to smart bombs!!! J Nucl Med 1993; 34: 2264-2268.
89. 2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: A multicenter study. Cancer Res 1989; 49: 3095-3103.
90. Becker W, Bair J, Behr T et al. Detection of soft-tisse infections and osteomyelitis using a technetium-99m labelled anti-granulocyte monoclonal antibody fragment. J Nucl Med 1994; 35: 1436-1443.
91. Bhatti M, Chapman P, Jamar F et al. Immunolocalization of active inflammatory bowel disease (IBD) using a monoclonal antibody against E-selectin. J Nucl Med 1996; 37(suppl. 5): 114P.
92. Chapman P, Jamar F, Haskard D, Peters A. Imaging arthritis: Comparison between In-111-anti-E-selectin monoclonal antibody and Tc-99m- and In-111-human immunoglobulin (abstract). J Nucl Med 1996; 37 (suppl. 5): 128P.
93. Epstein A, Chen F, Taylor C. A novel method for the detection of necrotic lesions in human cancer. Cancer Res 1988; 48: 5842-5848.
94. Thakur M, DeFulvio J, Park C et al. Evaluation of Tc-99m-labelled proteins for localisation of inflammation: Comparison with 1-125-TNT and Ga-67 citrate (abstract). J Nucl Med 1990; 31: 810.
95. Goldenberg D, Sharkey R, Udem S et al. Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients. J Nucl Med 1994; 35: 1028-1034.
96. Goodbody A, Ballinger J, Tran L et al. A new Tc-99m labelled peptide inflammation imaging agent (abtract). Eur J Nucl Med 1994; 21: 790.
97. Peers S, Tran L, Eriksonn S, Ballinger J, Goodbody A. Imaging a model of colitis with RP128, a Tc-99m-chelated tuftsin antagonist (abstract). J Nucl Med 1995; 36: 114P.
98. Nicola N, ed. Guidebook to cytokines and cytokine receptors. Oxford: Oxford University Press, 1994.
99. Van der Laken C, Boerman O, Oyen W et al. Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. Eur J Nucl Med 1995; 22: 1249-1255.
100. Van der Laken C, Boerman O, Oyen W et al. Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. Eur J Nucl Med 1996; 23: 1531-1535.
101. Semenzato G, Zambello R, Pizzolo G. Interleukin-2 receptor expression in health and disease. In: Waxman J, Balkwill F, eds. Interleukin-2. Oxford: Blackwell Scientific, 1992: 78-105.
102. Konrad M, Hemstreet G, Hersh E et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990; 50: 2009-2017.
103. Signore A, Parman A, Pozzilli P, Andreani D, Beverley P. Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123-iodine-labelled interleukin-2: An early sign of Type 1 diabetes. Lancet 1987; ii: 536-540.
104. Signore A, Chianelli M, Toscano A et al. A radiopharmaceutical for imaging areas of lymphocytic infiltration, 123I-interleukin-2 labelling procedure and animal studies. Nucl Med Commun 1992; 13: 713-722.
105. Signore A, Chianelli M, Ferretti E et al. Use of 123I interleukin-2 for in vivo detection of activated lymphocytes in chronic inflammatory conditions (abstract). Eur J Nucl Med 1993; 20: 834.
106. Signore A, Chianelli M, Ferretti E et al. In vivo imaging of activated lymphocytes in the pancreas of newly diagnosed diabetic patients (abstract). Diabetologia 1993; 36: A36.
107. Signore A, Picarelli A, Chianelli M et al. 123I-Interleukin-2 scintigraphy: A new approach to assess disease activity in autoimmunity. J Pediatr Endocrinol Metab 1996; 9: 139-144.
108. Signore A, Picarelli A, Maiuri L et al. 123I-IL2 for in vivo detection of activated lymphocytes: A scintigraphic and histological study in coeliac patients (abstract). Eur J Nucl Med 1995; 22: 794.
109. Chianelli M, Mather S, Procaccini E et al. In vivo detection of lymphocytic infiltration in thyroid autoimmune diseases. Eur J Nucl Med 1996; 23: 1055.
110. Barone R, Chianelli M, Bottoni U et al. In vivo detection of lymphocytic infiltration in melanoma using 99mTc-IL2. Eur J Nucl Med 1996; 23: 1217.
111. Hay R, Skinner R, Newman O et al. Nuclear imaging of acute inflammatory lesions with recombinant human interleukin-8 (abstract). J Nucl Med 1993; 37: 25P.
112. Gross M, Shapiro B, Skinner R et al. Scintigraphy of osteomyelitis in man with human recombinant interleukin-8. J Nucl Med 1996; 37(suppl. 5): 25P.
113. Vinjamuri S, Hall A, Solanki K et al. Comparison of 99mTc Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996; 347: 233-235.
114. Zoghbi S, Thakur M, Gottschalk A. Selective cell labelling: A potential radioactive agent for labeling of human neutrophils (abstract). J Nucl Med 1981; 22: 32P.
115. Fischmann A, Pike M, Kroon D et al. Imaging focal sites of bacterial infection in rats with indium-111-labelled chemotactic peptide analogs. J Nucl Med 1991; 32: 483-491.
116. Babich J, Solomon H, Pike M et al. Technetium-99m-labelled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med 1993; 34: 1964-1974.
117. Babich J, Graham W, Barrow S et al. Technetium-99m-labeled chemotactic peptides: Comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. J Nucl Med 1993; 34: 2176-2184.
118. Diot P, Pape AL, Nolibe D et al. Scintigraphy with J001X, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berilliosis: Results from an experimental model. Br J Int Med 1992; 49: 359-364.
119. Perin F, Pittet J, Hoffschir D et al. Scintigraphic potential of J001X acylated polygalactoside for imaging inflammatory lesions in pigs. Nucl Med Biol 1993; 20: 963-971.
120. Goupille P, Valat J-P, Le Pape, A. Imaging of synovitis in rheumatoid arthritis with radionuclide tracer. J Rheumatol 1994; 21: 1975-1976.
121. Miot-Noirault E, Perin F, Routledge L, Normier G, Pape AL. Macrophage targeting with technetium-99m labelled J001X acylated poly-galactoside for scintigraphy of inflammation: Optimisation and assessment of imaging specificity in experimental arthritis. Eur J Nucl Med 1996; 23: 61-68.
122. Diot P, Lemari E, Baulieu J et al. Scintigraphy with J001X macrophage targeting glycopolypeptide: A new approach for sarcoidosis imaging. Chest 1992; 102: 670-676.
123. Reubi J, Waser B, Horisberger U et al. In vitro autoradiographic and in vivo scintigraphic localisation of somatostatin receptors in human lymphatic tissue. Blood 1993; 82: 2143-2151.
124. Reubi J, Mazzucchelli L, Laissue J. Intestinal vessels express a high density of somatostatin receptor in human inflammatory bowel disease. Gastroenterology 1994; 106: 951-959.
125. Van Hagen P, Markusse H, Lamberts S et al. Somatostatin receptor imaging: The presence of somatostatin receptor in rheumatoid arthritis. Arthritis Rheum 1994; 37: 1521-1527.
126. Van Hagen P, Krenning E, Reubi J et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994; 21: 497-502.
127. Diaz M, Bockisch A, Kahaly G, Hahn K. Preliminary results of somatostatin receptor scintigraphy in endocrine ophthalmopathy (abstract). Eur J Nucl Med 1993; 20: 844.
128. Postema P, Wijnggaarde R, Vandenbosch W et al. Follow up in In-111-DTPA-D-Phe-1-octreotide scintigraphy in thyroidal and orbital Graves' disease (abstract). J Nucl Med 1995; 36: 203P.
129. Eberhardt J, Oberwöhrmann SO, Clausen M et al. Accumulation of 111In-Octreotide in the orbital and thyroid regions of patients with Graves' disease and with exophthalmos (abstract). Eur J Nucl Med 1993; 20: 844.
130. Bohuslavizki K, Oberwöhrmann SO, Brenner W et al. 111-In-octreotide imaging in patients with long-standing Graves' ophthalmopathy. Nucl Med Commun 1995; 16: 912-916.
131. Bahn R, Heufelder A. Pathogenesis of Graves' ophthalmopathy. N Eng J Med 1993; 329: 1468-1475.
132. Hurley J. Orbitopathy after treatment of Graves' disease. J Nucl Med 1994; 35: 918-920.
133. Oyen WJG, Boerman OC, Claessens RAMJ, van der Meer JWM, Corstens FHM. Is somatostatin receptor scintigraphy suited to detection of acute infection disease? Nucl Med Commun 1994; 15: 289-293.
134. Reubi J. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
135. Breeman W, Van Hagen M, Visser H et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med 1996; 37: 108-117.
136. Van Hagen M, Breeman W, Reubi J et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996; 23: 1508-1513.